A phase II study of loratidine (L) and naproxen (N) to prevent pegfilgrastim-induced pain (PIP).
Jeffrey J. Kirshner(American Society of Clinical Oncology), Gary R. Morrow(University of Rochester Medical Center), Carol Reichel, Charles E. Heckler(University of Rochester Medicine)
Cited by 2
Related Papers
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue
|JAMA Oncology|2017|913
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
|Journal of Clinical Oncology|2001|819
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
|Journal of Clinical Oncology|1999|670
Prevalence, Demographics, and Psychological Associations of Sleep Disruption in Patients With Cancer: University of Rochester Cancer Center–Community Clinical Oncology Program
|Journal of Clinical Oncology|2009|564
Applied Discriminant Analysis
|Technometrics|1995|409